162 related articles for article (PubMed ID: 12796064)
1. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis.
van Dongen CJ; Vink R; Hutten BA; Büller HR; Prins MH
Arch Intern Med; 2003 Jun; 163(11):1285-93. PubMed ID: 12796064
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.
Schulman S; Lindmarker P
N Engl J Med; 2000 Jun; 342(26):1953-8. PubMed ID: 10874063
[TBL] [Abstract][Full Text] [Related]
3. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
[TBL] [Abstract][Full Text] [Related]
4. Recurrent thromboembolism after treatment with vitamin K antagonists.
van Dongen CJ; Vink R; Hutten BA; Buller HR; Prins MH
Arch Intern Med; 2003 Dec 8-22; 163(22):2793. PubMed ID: 14662641
[No Abstract] [Full Text] [Related]
5. Long-term management of patients after venous thromboembolism.
Kearon C
Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
[TBL] [Abstract][Full Text] [Related]
6. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Hutten BA; Prins MH
Cochrane Database Syst Rev; 2000; (3):CD001367. PubMed ID: 10908494
[TBL] [Abstract][Full Text] [Related]
7. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S--a decision analysis.
van den Belt AG; Hutten BA; Prins MH; Bossuy PM
Thromb Haemost; 2000 Nov; 84(5):758-63. PubMed ID: 11127851
[TBL] [Abstract][Full Text] [Related]
8. [Duration of antivitamin K therapy in venous thromboembolic disease].
Ferrari E; Baudouy M; Morand P
Arch Mal Coeur Vaiss; 1995 Dec; 88(12):1891-4. PubMed ID: 8729371
[TBL] [Abstract][Full Text] [Related]
9. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Hutten BA; Prins MH
Cochrane Database Syst Rev; 2006 Jan; (1):CD001367. PubMed ID: 16437432
[TBL] [Abstract][Full Text] [Related]
10. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Koscielny J; Kiesewetter H; Jörg I; Harenberg J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
[TBL] [Abstract][Full Text] [Related]
11. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
13. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.
Dentali F; Ageno W; Witt D; Malato A; Clark N; Garcia D; McCool K; Siragusa S; Dyke S; Crowther M;
Thromb Haemost; 2009 Sep; 102(3):501-4. PubMed ID: 19718470
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
Farraj RS
Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
[TBL] [Abstract][Full Text] [Related]
15. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.
Brouwer JL; Lijfering WM; Ten Kate MK; Kluin-Nelemans HC; Veeger NJ; van der Meer J
Thromb Haemost; 2009 Jan; 101(1):93-9. PubMed ID: 19132194
[TBL] [Abstract][Full Text] [Related]
16. Duration of anticoagulation in venous thromboembolism.
Hyers TM
Arch Intern Med; 2003 Jun; 163(11):1265-6. PubMed ID: 12796061
[No Abstract] [Full Text] [Related]
17. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
18. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
Eischer L; Gartner V; Schulman S; Kyrle PA; Eichinger S;
Ann Hematol; 2009 May; 88(5):485-90. PubMed ID: 18931845
[TBL] [Abstract][Full Text] [Related]
19. [Secondary prophylaxis of venous thromboembolism].
Sternitzky R; Hochauf S; Schellong SM
Hamostaseologie; 2007 Feb; 27(1):32-40. PubMed ID: 17279274
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of venous thrombosis in cancer patients: practical aspects].
Laza-Achille M; Desruennes E; Di Palma M
Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
